Loading...
•
Jun 30
Co-Diagnostics Q2 2025 Earnings Report
Co-Diagnostics posted a net loss in Q2 2025 as revenue declined significantly due to the absence of grant revenue.
Key Takeaways
Co-Diagnostics reported a net loss of $7.7 million in Q2 2025 as revenue dropped to $0.16 million due to the lack of grant revenue. Operating expenses were reduced year-over-year, but the company continues to invest in its Co-Dx PCR platform.
Revenue declined to $162,910, down from $2.7 million in Q2 2024.
Net loss was $7.7 million or $0.23 per share.
Adjusted EBITDA loss was $7.2 million.
Cash and marketable securities totaled $13.4 million.
Co-Diagnostics
Co-Diagnostics
Co-Diagnostics Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Co-Diagnostics plans to initiate clinical evaluations for all Co-Dx PCR platform tests before year-end, with regulatory submissions to follow.
Positive Outlook
- Clinical site training underway for enhanced COVID-19 test
- Clinical evaluations planned for all tests by year-end
- Strong investment in regulatory and development infrastructure
- PCR platform expected to drive long-term growth
- Company confident in quality of Co-Dx platform
Challenges Ahead
- No grant revenue recognized in Q2 2025
- Continued operating and net losses
- Decline in total assets and equity from previous year
- Limited revenue diversification
- Regulatory approvals still pending for key products